STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

KNOBLOCH Information Group, BEN, and Skye Inteligencia LATAM Form Skye Salud to Modernize Healthcare in Mexico with Sovereign AI

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
AI

Brand Engagement Network (Nasdaq: BNAI), Skye Inteligencia LATAM and KNOBLOCH Information Group formed Skye Salud, a Mexican S.A.P.I. to deploy a nationwide sovereign augmented‑intelligence healthcare platform.

The platform targets initial Q1 2026 pilots and aims to modernize workflows, ambient scribing, predictive alerts, and population‑health insights across a system serving >130 million people. BEN will receive 35% of applicable gross revenues via its license agreement with Skye Inteligencia LATAM. KNOBLOCH contributes proprietary datasets covering ~85% of the Mexican pharmaceutical market and audits ~99% of the private pharma market.

Loading...
Loading translation...

Positive

  • BEN revenue share of 35% of applicable gross revenues
  • EHR/EMR market projected from $2.4B (2025) to $5.3B (2031)
  • Platform targets Q1 2026 pilot deployments
  • KNOBLOCH datasets cover ~85% of Mexican pharma market
  • Initiative targets healthcare system serving >130M people

Negative

  • BEN revenue contingent on Skye Inteligencia LATAM operations
  • Skye Inteligencia LATAM holds 2 of 3 board seats

News Market Reaction 3 Alerts

-3.73% News Effect
+848.7% Peak Tracked
-$513K Valuation Impact
$13M Market Cap
0.0x Rel. Volume

On the day this news was published, BNAI declined 3.73%, reflecting a moderate negative market reaction. Argus tracked a peak move of +848.7% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $513K from the company's valuation, bringing the market cap to $13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Population served over 130 million people Mexico healthcare system Skye Salud aims to support
Adults with diabetes over 14 million Chronic-disease burden in Mexico highlighted in article
EHR/EMR market 2025 USD $2.4 billion Mexico EHR and EMR market size in 2025
EHR/EMR market 2031 USD $5.3 billion Projected Mexico EHR and EMR market size by 2031
Revenue share 35% of applicable gross revenues BEN’s share from Skye Inteligencia LATAM operations including Skye Salud
Skye Salud ownership 50% / 50% Equal ownership split between Skye Inteligencia LATAM and KNOBLOCH Information Group
Market audited 99% of private pharma market Share of Mexico’s private pharmaceutical market audited by KNOBLOCH
Institutions tracked 82 institutions Panel providing real-time sell-out data to KNOBLOCH Information Group

Market Reality Check

$2.58 Last Close
Volume Volume 645,429 is about 0.35x the 20-day average of 1,833,961, indicating subdued trading ahead of this AI partnership news. low
Technical Shares trade below the 200-day MA of $0.36, at a pre-news price of $0.295, reflecting a longer-term downtrend.

Peers on Argus 1 Down

Pre-news, BNAI was down 4.16% while key peers showed mixed moves: FAAS (-8.3%), BLIN (-1.87%), OLB (-1.1%), DTSS (+2.5%), NEHC (+11.46%). With only one momentum peer (RVYL at -5.57%) and no broad, same-direction move, trading appeared more stock-specific than sector-driven.

Historical Context

Date Event Sentiment Move Catalyst
Dec 08 AI healthcare launch Positive +7.5% Initial announcement of Skye Salud sovereign healthcare AI platform for Mexico.
Dec 02 Reverse stock split Negative -10.7% 1‑for‑10 reverse split to address Nasdaq minimum bid-price compliance.
Nov 10 AI licensing deal Positive +28.4% Finalized $5M exclusive AI licensing partnership with SKYE LATAM in Latin America.
Oct 14 Quarterly earnings Positive -6.9% Q2 2025 results with sharply lower expenses and net income from debt extinguishment.
Oct 14 AI leadership, product Positive -3.2% Board appointment of Dr. Carrasco and plans to debut an insurance AI agent.
Pattern Detected

News has often moved the stock, with positive strategic AI and partnership updates tending to see upside, while structurally negative or complex items (reverse split, going‑concern backdrop) have drawn selling. There is a mixed pattern around operational and governance news, with some positive announcements still followed by declines.

Recent Company History

Over the last six months, BNAI has focused on building an AI-led platform business while managing financial strain. In October 2025, Q2 results showed minimal revenue but net income driven by debt extinguishment. A major AI licensing deal with SKYE LATAM in November 2025 brought $5,000,000 in preferred equity and a 35% revenue share. The company then proposed and approved a 1‑for‑10 reverse split in December 2025. Just days before today’s announcement, BEN and Skye Inteligencia first introduced the Skye Salud initiative, setting the stage for this expanded partnership.

Market Pulse Summary

This announcement deepens BEN’s AI expansion in Latin America by formalizing Skye Salud, a sovereign, Spanish‑language healthcare platform built on KNOBLOCH’s extensive pharmaceutical data. It reinforces the earlier SKYE LATAM licensing deal and targets pilots in Q1 2026 across public hospitals and chronic‑disease programs. Against recent 10‑Q disclosures of low revenue and tight liquidity, key metrics to watch include pilot adoption, realized revenue from the 35% gross‑revenue share, and any follow-on financing activity.

Key Terms

sovereign augmented-intelligence platform technical
"to deploy Mexico's first nationwide sovereign augmented-intelligence platform"
A sovereign augmented-intelligence platform is a software system that combines human-guided artificial intelligence with measures to keep data and control within a specific country or government’s rules. Think of it as a local, high-tech assistant that helps people analyze information while ensuring sensitive data stays under national oversight. Investors care because such platforms can unlock government contracts, reduce regulatory risk, and command premium pricing where data residency and official approval are required.
Electronic Medical Records (EMRs) medical
"paper records or fragmented Electronic Medical Records (EMRs)"
Electronic medical records (EMRs) are digital versions of a patient’s paper chart kept by a single healthcare provider or clinic, like a secure, searchable filing cabinet for medical history, test results and treatment notes. Investors care because EMRs are a core operational asset that affects a provider’s efficiency, billing, regulatory compliance, potential for software sales or subscriptions, and exposure to data-security and interoperability risks that can influence costs and revenue.
EHR medical
"Mexico's EHR and EMR market to grow from USD $2.4 billion"
EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.
CAGR financial
"to USD $5.3 billion by 2031 at approximately 14% CAGR"
Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.
ambient scribing technical
"support clinicians with ambient scribing, structured documentation, predictive alerts"
Ambient scribing is an automated system that listens to real-world conversations—such as doctor visits, earnings calls, or meetings—and creates written records and summaries without manual note-taking. Like a silent assistant that fills out forms and highlights key points, it can speed workflows, reduce labor costs and improve accuracy, but it also raises questions about data privacy, security and regulatory compliance that investors must weigh when assessing risks and potential savings.
population-health insights medical
"predictive alerts, and population-health insights—all designed to augment"
Aggregated findings about the health, diseases, care use and costs of a defined group of people, produced by analyzing medical records, claims, surveys or wearable data to reveal patterns and risks. Investors use these insights like a community weather report — they show where demand, treatment gaps, cost pressures or preventive opportunities are growing, helping assess market size, revenue potential and regulatory or reimbursement risks for healthcare products and services.
SOAP-note medical
"Key Features: One-tap ambient SOAP-note generation, predictive clinical insights"
A SOAP note is a standard medical record format that organizes patient encounters into four parts—what the patient reports (Subjective), what clinicians observe or measure (Objective), the clinician’s diagnosis or impression (Assessment), and the next steps or treatment (Plan). For investors, SOAP notes matter because they are core evidence of clinical care and study conduct; clear, consistent notes support regulatory compliance, reliable clinical data and lower legal or operational risk, much like a detailed receipt and checklist for a complex project.
sovereign AI technical
"combined with our sovereign AI technology, creates a powerhouse"
An AI system described as "sovereign" is built, hosted, or operated under a country’s legal and technical control so that data, code, and decision-making stay within that jurisdiction. For investors, sovereign AI matters because it affects which vendors can sell to governments or regulated industries, imposes compliance and infrastructure costs, and can create protected local markets—similar to a factory that must follow a nation’s building codes and can only sell to certain buyers.

AI-generated analysis. Not financial advice.

WILMINGTON, Del. and MEXICO CITY, Dec. 11, 2025 /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) ("BEN"), a developer of secure, governed multimodal AI for regulated industries, together with Skye Inteligencia LATAM and KNOBLOCH Information Group, Mexico's premier healthcare data authority, today announced the formation of Skye Salud, a new Mexican S.A.P.I. established under a binding agreement to deploy Mexico's first nationwide sovereign augmented-intelligence platform. This landmark venture is poised to modernize clinical workflows, enhance patient safety, and dramatically expand access to high-quality care across a healthcare system serving over 130 million people.

Addressing Urgent Challenges in a Massive, High-Growth Market. 

A Transformational Partnership with KNOBLOCH Information Group: Mexico's Premier Healthcare Data Authority. Mexico's healthcare system faces escalating chronic-disease burdens—including over 14 million adults living with diabetes, alongside widespread hypertension and cardiovascular conditions—while many institutions remain reliant on paper records or fragmented Electronic Medical Records (EMRs). These gaps hinder care continuity, diagnostic accuracy, and efficiency. Independent industry research projects Mexico's EHR and EMR market to grow from USD $2.4 billion in 2025 to USD $5.3 billion by 2031 at approximately 14% CAGR, with this robust double-digit compound annual growth accelerating through 2031 as institutions shift from paper-based workflows to modern digital systems.

Skye Salud is being developed as a secure, Spanish-language native platform designed to integrate seamlessly with existing systems. The platform, targeted for initial Q1 2026 pilots, is intended to support clinicians with ambient scribing, structured documentation, predictive alerts, and population-health insights—all designed to augment, not replace, human judgment.

A Transformational Partnership with KNOBLOCH Information Group: Mexico's Premier Healthcare Data Authority - Skye Salud was formed under a binding agreement between Skye Inteligencia LATAM and KNOBLOCH Information Group, with both holding an equal 50% ownership. Through BEN's existing licensing and shareholder agreements with Skye Inteligencia LATAM, BEN, under its license agreement, will receive 35% of applicable gross revenues generated by Skye Inteligencia LATAM's operations, including those related to Skye Salud. This structure aligns long-term incentives across all partners and reinforces BEN's revenue opportunities as the platform scales. Skye Inteligencia LATAM will hold two of the three board seats.

The defining strength of Skye Salud is the strategic partnership with KNOBLOCH Information Group, one of Mexico's most respected and influential leaders in pharmaceutical market intelligence and healthcare infrastructure. Founded in 2000 by Juan Knobloch, M., Director General of KNOBLOCH Information Group, the company is the country's leading independent provider of audited sell-out data for the private pharmaceutical market, competing directly with global giants.

Key public metrics underscore KNOBLOCH Information Group's unmatched scale and dominance:

  • Audits 99% of Mexico's private pharmaceutical market, which represents approximately 74% of the total pharmaceutical market.
  • Tracks real-time sell-out data from a panel of 82 institutions, including national and regional wholesalers, drugstore chains, supermarkets, generic wholesalers, and telemarketing firms.
  • Captures data encompassing billions of units sold annually, providing granular insights into pricing, distribution, sales trends, and product launches.
  • Delivers the foundational data used to compensate an estimated 70% of pharmaceutical sales representatives in Mexico through its A.T.V.® Territorial Sales Management system.
  • Covers nearly 85% of the overall Mexican pharmaceutical market at the sell-out level, including 70% from direct sell-out information.
  • Audits alternative channels that now account for about 37% of the private market in units, including low-priced branded generics and private labels (representing ~12% of total private market volume).

Access to comprehensive, real-time pharmaceutical data has historically been a significant barrier for effective AI deployment in healthcare markets like Mexico's. KNOBLOCH Information Group's extensive, proprietary datasets—built over decades of auditing and analysis—provide a critical foundation for overcoming this challenge, enabling data-informed clinical intelligence at scale.

With decades of strong relationships across public institutions, including the Instituto Mexicano del Seguro Social (IMSS) and the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), as well as pharmacy networks and regional health authorities, KNOBLOCH Information Group offers unmatched operational expertise, regulatory guidance, and local execution—speeding up Skye Salud's journey to nationwide adoption.

"Partnering with KNOBLOCH Information Group is transformative for BEN and for healthcare in Mexico," said Tyler Luck, Acting CEO of BEN. "Their dominant position in pharmaceutical data and intelligence, combined with our sovereign AI technology, creates a powerhouse capable of driving real, scalable improvements in clinical care for millions."

"Skye Salud unites our extensive healthcare data infrastructure and national reach with cutting-edge augmented intelligence tailored for Mexico," said Juan Knobloch, M., Director General of KNOBLOCH Information Group. "Together, we are laying the foundation for a modern, secure digital ecosystem that can support more consistent and efficient care across the country."

World-Class Clinical Leadership - Skye Salud benefits from oversight by two renowned BEN board members: Dr. Richard Isaacs, a nationally recognized head and neck oncologic surgeon and former CEO of The Permanente Medical Group and The Permanente Federation, where he oversaw care delivery for more than 13 million patients and led one of the nation's most significant clinical-technology modernization initiatives; and Dr. Ruy Carrasco, a U.S. citizen with Mexican heritage and a distinguished pediatric rheumatologist whose career has focused on improving chronic-disease management and advancing health-equity outcomes for underserved communities across the U.S. and Mexico.

Their combined experience leading large-scale clinical operations, advancing digital modernization, and improving chronic-disease outcomes ensures that Skye Salud's development roadmap is guided by physician-executives deeply attuned to the realities of frontline care.

Dr. Isaacs stated that "Mexico's opportunity to strengthen quality care and reduce—or potentially eliminate—preventable medical errors coupled with rapid digital-health modernization, reflects broader global trends, with analysts projecting strong double-digit CAGR growth in the country's EHR and EMR market through 2031—reinforcing the strategic importance of building secure, scalable clinical infrastructure through Skye Salud."

With physician leadership and strategic partnerships guiding development, Skye Salud is being structured around five foundational pillars:

Skye Salud's Five Pillars of Excellence:

  • Data Access: Leveraging KNOBLOCH Information Group's real-time pharma intelligence.
  • Patient Safety: Predictive Alerts for high-risk conditions.
  • Operational Efficiency: Ambient scribing and seamless EMR integration.
  • Personalized Care: Spanish-native tools for frontline clinicians.
  • Population Health Insights: Proactive monitoring at scale.
    Key Features: One-tap ambient SOAP-note generation, predictive clinical insights, and phased rollout targeted for Q1 2026 pilot programs in public hospitals, pharmacy clinics, and chronic-disease programs.

A Phased Roadmap Toward National Deployment - Pilot programs are expected to launch in the first quarter of 2026 across public hospitals, pharmacy-based clinics, state chronic-disease programs, regional health authorities, and medical education institutions, with a broader rollout to follow.

Together, KNOBLOCH Information Group's national data infrastructure, BEN's sovereign AI technology, and Skye Inteligencia LATAM's regional expertise form a uniquely strong foundation for advancing healthcare modernization and increasing access to high-quality clinical support across Mexico.

Skye Salud represents a coordinated commitment to building secure, scalable digital infrastructure that supports the future of healthcare delivery across Mexico.

About Brand Engagement Network, Inc. (BEN): Brand Engagement Network, Inc. (Nasdaq: BNAI) develops conversational AI agents for regulated industries. Its ELM™ with retrieval-augmented generation powers multimodal, compliance-focused AI across chat, voice, avatar, and digital channels. With 21 issued patents and adoption in life sciences, healthcare, insurance, financial services, hospitality, retail, and automotive, BEN remains at the forefront of enterprise AI and regulatory standards. Visit www.beninc.ai.

About Skye Salud: Skye Salud is a Mexican S.A.P.I. formed by Skye Inteligencia LATAM and KNOBLOCH Information Group to modernize healthcare delivery. The sovereign, Spanish- native platform is being developed to integrate with existing systems to strengthen documentation, safety, and access nationwide.

About Skye Inteligencia LATAM: Skye Inteligencia LATAM deploys secure, sovereign AI solutions for Latin America's regulated sectors, through its partnership with BEN to address critical infrastructure challenges in healthcare, government, and enterprises.

About KNOBLOCH Information Group: Founded in 2000, KNOBLOCH Information Group is Mexico's leading independent provider of pharmaceutical market intelligence, delivering audited sell-out data and territorial sales management tools that power decision-making for the industry's largest stakeholders.

Forward-Looking Statements: Certain statements in this communication are "forward-looking statements" within the meaning of federal securities laws. They are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect, among other things, BEN's current expectations, assumptions, plans, strategies, and anticipated results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. There are a number of risks, uncertainties and conditions that may cause BEN's actual results to differ materially from those expressed or implied by these forward-looking statements, including but not limited to the risk factors described in Part I, Item 1A of Risk Factors in BEN's Annual Report on Form 10-K for the year ended December 31, 2024 and the other risk factors identified from time to time in BEN's other filings with the Securities and Exchange Commission (the "SEC"). These forward-looking statements may include words such as "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "should," "may," "will," "might," "could," "would," or similar expressions.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/knobloch-information-group-ben-and-skye-inteligencia-latam-form-skye-salud-to-modernize-healthcare-in-mexico-with-sovereign-ai-302639146.html

SOURCE Brand Engagement Network, Inc. (BEN)

FAQ

What is Skye Salud and which companies launched it (BNAI)?

Skye Salud is a Mexican S.A.P.I. formed by BEN (Nasdaq: BNAI), Skye Inteligencia LATAM and KNOBLOCH to build a sovereign augmented‑intelligence healthcare platform.

When will Skye Salud begin pilots and where (BNAI)?

Skye Salud targets initial pilot programs in Q1 2026 across public hospitals, pharmacy clinics, and chronic‑disease programs.

How much revenue share will BEN (BNAI) receive from Skye Salud operations?

Under BEN's license agreement, BEN will receive 35% of applicable gross revenues generated by Skye Inteligencia LATAM's operations.

What market data does KNOBLOCH contribute to Skye Salud (BNAI)?

KNOBLOCH provides proprietary real‑time pharma intelligence covering about 85% of the Mexican pharmaceutical market and auditing ~99% of private pharma sell‑out.

What clinical features will Skye Salud provide in Mexico (BNAI)?

The platform offers Spanish‑native ambient scribing, one‑tap SOAP notes, predictive alerts, structured documentation, and population‑health insights.

How large is the Mexican healthcare population Skye Salud aims to serve (BNAI)?

Skye Salud intends to serve a healthcare system covering more than 130 million people in Mexico.
Brand Engagement

NASDAQ:BNAI

BNAI Rankings

BNAI Latest News

BNAI Latest SEC Filings

BNAI Stock Data

12.82M
2.78M
40.21%
7.16%
0.12%
Software - Infrastructure
Services-computer Integrated Systems Design
Link
United States
JACKSON